REYON PHARMACEUTICAL's corporate governance report reveals multiple deficiencies in dividend policy, CEO succession, and internal controls, posing long-term governance risks
[AI Summary]REYON PHARMACEUTICAL's governance report highlights significant deficiencies in shareholder return policies and internal control systems, particularly the absence of dividends and a CEO succession plan, which may impede long-term shareholder value enhancement. Potential dilution from convertible bonds and persistent operating losses add financial uncertainty, but positive aspects like an outside director-led audit committee exist. Therefore, the short-term impact is neutral, but governance improvements will be a key factor for future stock performance.